Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma

References

• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet371, 1030–1043 (2008).
   PubMed Web of Science ®Google Scholar
• Sung L, Aplenc R, Zaoutis T, Groll AH, Gibson B, Lehrnbecher T. Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions. Pediatr. Blood Cancer51, 458–460 (2008).
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia19, 2025–2029 (2005).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Koehl U, Wittekindt B et al. Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncol.9, 269–278 (2008).
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann. Intern. Med.64, 328–340 (1966).
   PubMed Web of Science ®Google Scholar
• Schimpff S, Satterlee W, Young V, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile, patients with cancer and granulocytopenia. N. Engl. J. Med.284, 1061–1065 (1971).
   PubMed Web of Science ®Google Scholar
• Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann. Intern. Med.77, 707–714 (1972).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br. J. Haematol.116, 28–56 (2002).
   PubMed Web of Science ®Google Scholar
• Metcalf D. Hematopoietic cytokines. Blood111, 485–491 (2008).
   PubMed Web of Science ®Google Scholar
• Gasson JC. Molecular physiology of granulocyte–macrophage colony-stimulating factor. Blood77, 1131–1145 (1991).
   PubMed Web of Science ®Google Scholar
• Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood88, 1907–1929 (1996).
   PubMed Web of Science ®Google Scholar
• Strife A, Lambek C, Wisniewski D et al. Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells. Blood69, 1508–1523 (1987).
   PubMed Web of Science ®Google Scholar
• Chen BD, Clark CR, Chou TH. Granulocyte/macrophage colony-stimulating factor stimulates monocyte and tissue macrophage proliferation and enhances their responsiveness to macrophage colony-stimulating factor. Blood71, 997–1002 (1988).
   PubMedGoogle Scholar
• Chen BD, Mueller M, Chou TH. Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J. Immunol.141, 139–144 (1988).
   PubMed Web of Science ®Google Scholar
• Spiekermann K, Roesler J, Emmendoerffer A, Elsner J, Welte K. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia11, 466–478 (1997).
   PubMed Web of Science ®Google Scholar
• Gadish M, Kletter Y, Flidel O, Nagler A, Slavin S, Fabian I. Effects of recombinant human granulocyte and granulocyte–macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. Leuk. Res.15, 1175–1182 (1991).
   PubMed Web of Science ®Google Scholar
• Fabian I, Kletter Y, Bleiberg I, Gadish M, Naparsteck E, Slavin S. Effect of exogenous recombinant human granulocyte and granulocyte–macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. Exp. Hematol.19, 868–873 (1991).
   PubMed Web of Science ®Google Scholar
• Gil-Lamaignere C, Winn RM, Simitsopoulou M, Maloukou A, Walsh TJ, Roilides E. Inteferon g and granulocyte–macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med. Mycol.43, 253–260 (2005).
   PubMed Web of Science ®Google Scholar
• Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-g and granulocyte–macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J. Infect. Dis.191, 1180–1187 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen DM, Bhalla SC, Anaissie EJ, Hester JP, Savary CA, Rex JH. Effects of in vitro and in vivo cytokine treatment, leukapheresis and irradiation on the function of human neutrophils. Clin. Lab. Haematol.19, 39–47 (1997).
   PubMedGoogle Scholar
• Fleischmann J, Golde DW, Weisbart RH, Gasson JC. Granulocyte–macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood68, 708–711 (1986).
   PubMed Web of Science ®Google Scholar
• Villalta F, Kierszenbaum F. Effects of human colony-stimulating factor on the uptake and destruction of a pathogenic parasite (Trypanosoma cruzi) by human neutrophils. J. Immunol.137, 1703–1707 (1986).
   PubMedGoogle Scholar
• Baldwin GC, Gasson JC, Quan SG et al. Granulocyte–macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome. Proc. Natl Acad. Sci. USA85, 2763–2766 (1988).
   PubMed Web of Science ®Google Scholar
• Baldwin GC, Fuller ND, Roberts RL, Ho DD, Golde DW. Granulocyte- and granulocyte–macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells. Blood74, 1673–1677 (1989).
   PubMedGoogle Scholar
• Kropec A, Lemmen SW, Grundmann HJ, Engels I, Daschner FD. Synergy of simultaneous administration of ofloxacin and granulocyte colony-stimulating factor in killing Escherichia coli by human neutrophils. Infection23, 298–300 (1995).
   PubMedGoogle Scholar
• Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol.24, 3187–3205 (2006).
   PubMed Web of Science ®Google Scholar
• Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M; International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br. J. Haematol.99, 580–588 (1997).
   PubMed Web of Science ®Google Scholar
• Lydaki E, Bolonaki E, Stiakaki E, Dimitriou H, Kalmantis T, Kalmanti M. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte–macrophage colony-stimulating factor in neutropenic children with malignancies. Pediatr. Hematol. Oncol.12, 551–558 (1995).
   PubMed Web of Science ®Google Scholar
• Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J. Clin. Oncol.18, 43–53 (2000).
   PubMed Web of Science ®Google Scholar
• Dubois RW, Pinto LA, Bernal M, Badamgarav E, Lyman GH. Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature. Support. Cancer Ther.2, 34–41 (2004).
   PubMedGoogle Scholar
• Buonadonna A, Frustaci S, Galligioni E, Gigante M, Monfardini S. Comparison between G-CSF and GM-CSF for prophylaxis of severe leukopenia after intensive chemotherapy. Proc. Am. Soc. Clin. Oncol.13, 462 (Abstract) (1994).
   Google Scholar
• Dimitrov N, Stoller R, Hamm J. A NSABP pilot study evaluating GM-CSF and G-CSF used with high-dose chemotherapy. Proc. Am. Soc. Clin. Oncol.12, 138 (Abstract) (1993).
   Google Scholar
• Kubota M, Akiyama Y, Mikawa H, Tsutsui T. Comparative effect of 100 versus 250 micrograms/m2/day of G-CSF in pediatric patients with neutropenia induced by chemotherapy. Pediatr. Hematol. Oncol.12, 393–397 (1995).
   PubMed Web of Science ®Google Scholar
• Cairo MS, Shen V, Krailo MD et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J. Pediatr. Hematol. Oncol.23, 30–38 (2001).
   PubMed Web of Science ®Google Scholar
• Petros WP. Pharmacokinetics and administration of colony-stimulating factors. Pharmacotherapy12, S32–S38 (1992).
   Google Scholar
• Rosenfeld CS, Sulecki M, Evans C, Shadduck RK. Comparison of intravenous versus subcutaneous recombinant human granulocyte–macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp. Hematol.19, 273–277 (1991).
   PubMed Web of Science ®Google Scholar
• Calderwood S, Romeyer F, Blanchette V et al. Concurrent rhGM-CSF does not offset myelosuppression from intensive chemotherapy: randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am. J. Hematol.47, 27–32 (1994).
   PubMedGoogle Scholar
• Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood109, 936–943 (2007).
   PubMed Web of Science ®Google Scholar
• Rubino C, Laplanche A, Patte C, Michon J. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin’s lymphoma. J. Natl Cancer Inst.90, 750–755 (1998).
   PubMedGoogle Scholar
• Patte C, Laplanche A, Bertozzi AI et al. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin’s lymphoma: a randomized study of the French Society of Pediatric Oncology. J. Clin. Oncol.20, 441–448 (2002).
   PubMed Web of Science ®Google Scholar
• Laver J, Amylon M, Desai S et al. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J. Clin. Oncol.16, 522–526 (1998).
   PubMed Web of Science ®Google Scholar
• Little MA, Morland B, Chisholm J et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med. Pediatr. Oncol.38, 98–103 (2002).
   PubMedGoogle Scholar
• Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann. Intern. Med.147, 400–411 (2007).
   PubMed Web of Science ®Google Scholar
• Saarinen-Pihkala UM, Lanning M, Perkkio M et al. Granulocyte–macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med. Pediatr. Oncol.34, 319–327 (2000).
   PubMedGoogle Scholar
• Kalmanti M, Lydaki E, Dimitriou H et al. Effect of granulocyte colony-stimulating factor on chemotherapy-induced neutropenia in children with cancer. Pediatr. Hematol. Oncol.11, 147–155 (1994).
   PubMed Web of Science ®Google Scholar
• Riikonen P, Rahiala J, Salonvaara M, Perkkio M. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells13, 289–294 (1995).
   PubMed Web of Science ®Google Scholar
• Welte K, Reiter A, Mempel K et al.; Berlin–Frankfurt–Münster Study Group. A randomized Phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood87, 3143–3150 (1996).
   PubMed Web of Science ®Google Scholar
• Pui CH, Boyett JM, Hughes WT et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N. Engl. J. Med.336, 1781–1787 (1997).
   PubMed Web of Science ®Google Scholar
• Chen SH, Liang DC, Liu HC. High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia. Am. J. Hematol.58, 20–23 (1998).
   PubMedGoogle Scholar
• Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med. Pediatr. Oncol.32, 331–335 (1999).
   PubMedGoogle Scholar
• Michel G, Landman-Parker J, Auclerc MF et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J. Clin. Oncol.18, 1517–1524 (2000).
   PubMed Web of Science ®Google Scholar
• Heath JA, Steinherz PG, Altman A et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children’s Cancer Group Study. J. Clin. Oncol.21, 1612–1617 (2003).
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis.34, 730–751 (2002).
   PubMed Web of Science ®Google Scholar
• Souza LM, Boone TC, Gabrilove J et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science232, 61–65 (1986).
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood81, 281–292 (1993).
   PubMed Web of Science ®Google Scholar
• Griffin J, Young D, Hermann F, Wiper D, Wagner K, Sabbath K. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood67, 1448–1453 (1986).
   PubMed Web of Science ®Google Scholar
• Motoji T, Watanabe M, Uzumaki H et al. Granulocyte colony-stimulating factor (G-CSF) receptors on acute myeloblastic leukaemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay. Br. J. Haematol.77, 54–59 (1991).
   PubMed Web of Science ®Google Scholar
• Bruserud O, Ryningen A, Olsnes AM et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica92, 332–341 (2007).
   PubMed Web of Science ®Google Scholar
• Rowe JM, Andersen JW, Mazza JJ et al. A randomized placebo-controlled Phase III study of granulocyte–macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E 1490). Blood86, 457–462 (1995).
   PubMed Web of Science ®Google Scholar
• Stone R, Berg D, George S et al. Granulocyte–macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N. Engl. J. Med.332, 1671–1677 (1995).
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA et al.; The International Acute Myeloid Leukemia Study Group. A randomized, double-blind, placebo-controlled, Phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood90, 4710–4718 (1997).
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky KJ, Head DR et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood91, 3607–3615 (1998).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML–BFM 93. Leukemia18, 72–77 (2004).
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Lehrnbecher T et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML–BFM 98. J. Clin. Oncol.24, 4499–4506 (2006).
   PubMed Web of Science ®Google Scholar
• Dombret H, Chastang C, Fenaux P et al.; AML Cooperative Study Group. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N. Engl. J. Med.332, 1678–1683 (1995).
   PubMed Web of Science ®Google Scholar
• Heil G, Chadid L, Hoelzer D et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia9, 3–9 (1995).
   PubMed Web of Science ®Google Scholar
• Usuki K, Urabe A, Masaoka T et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br. J. Haematol.116, 103–112 (2002).
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Jehn U et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized Phase-3 study. Blood106, 27–34 (2005).
   PubMed Web of Science ®Google Scholar
• Alonzo TA, Kobrinsky NL, Aledo A, Lange BJ, Buxton AB, Woods WG. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children’s Cancer Group. J. Pediatr. Hematol. Oncol.24, 627–635 (2002).
   PubMedGoogle Scholar
• Burdach SE, Muschenich M, Josephs W et al. Granulocyte–macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. Cancer76, 510–516 (1995).
   PubMed Web of Science ®Google Scholar
• Furman WL, Fairclough DL, Huhn RD et al. Therapeutic effects and pharmacokinetics of recombinant human granulocyte–macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J. Clin. Oncol.9, 1022–1028 (1991).
   PubMed Web of Science ®Google Scholar
• Levine JE, Boxer LA. Clinical applications of hematopoietic growth factors in pediatric oncology. Curr. Opin. Hematol.9, 222–227 (2002).
   PubMed Web of Science ®Google Scholar
• Schaison G, Eden OB, Henze G et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur. J. Pediatr.157, 955–966 (1998).
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte–macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J. Clin. Oncol.22, 3350–3356 (2004).
   PubMed Web of Science ®Google Scholar
• Wittman B, Horan J, Lyman GH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat. Rev.32, 289–303 (2006).
   PubMed Web of Science ®Google Scholar
• Sasse EC, Sasse AD, Brandalise S, Clark OA, Richards S. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst. Rev.3, CD004139 (2005).
   Google Scholar
• Channa J, Hashmi KZ. Role of recombinant granulocyte–macrophage colony-stimulating factor in reducing the duration of neutropenia. J. Coll. Physicians Surg. Pak.12, 538–541 (2002).
   Google Scholar
• Dibenedetto SP, Ragusa R, Ippolito AM et al. Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. Eur. J. Haematol.55, 93–96 (1995).
   PubMedGoogle Scholar
• Bennett CL, Stinson TJ, Laver JH, Bishop MR, Godwin JE, Tallman MS. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk. Lymphoma37, 65–70 (2000).
   PubMed Web of Science ®Google Scholar
• Relling MV, Boyett JM, Blanco JG et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood101, 3862–3867 (2003).
   PubMed Web of Science ®Google Scholar
• Graubner UB, Porzig S, Jorch N et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer50, 259–263 (2008).
   PubMed Web of Science ®Google Scholar
• Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood110, 3532–3539 (2007).
   PubMed Web of Science ®Google Scholar
• Mitchell PLR, Morland B, Stevens MCG et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J. Clin. Oncol.15, 1163–1170 (1997).
   PubMed Web of Science ®Google Scholar
• Riikonen P, Saar inen UM, Mäkipernaa A et al. Recombinant human granulocyte–macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr. Infect. Dis. J.13, 197–202 (1994).
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children’s Oncology Group. Pediatr. Blood Cancer45, 274–280 (2005).
   PubMed Web of Science ®Google Scholar
• Berghmans T, Paesmans M, Lafitte JJ et al. Therapeutic use of granulocyte and granulocyte–macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support. Care Cancer10, 181–188 (2002).
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J. Clin. Oncol.23, 4198–4214 (2005).
   PubMed Web of Science ®Google Scholar
• Schoepfer C, Carla H, Bezou MJ et al.Malassezia furfur septicemia after bone marrow graft. Arch. Pediatr.2, 245–248 (1995).
   PubMedGoogle Scholar
• Liang DC, Chen SH, Lean SF. Role of granulocyte colony-stimulating factor as adjunct therapy for septicemia in children with acute leukemia. Am. J. Hematol.48, 76–81 (1995).
   PubMedGoogle Scholar
• Anaissie EJ, Vartivarian S, Bodey GP et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte–macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am. J. Med.100, 17–23 (1996).
   PubMed Web of Science ®Google Scholar
• Dignani MC, Rex JH, Chan KW et al. Immunomodulation with interferon-g and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer104, 199–204 (2005).
   PubMed Web of Science ®Google Scholar
• Mackall C, Fleisher T, Brown M et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood84, 2221–2228 (1994).
   PubMed Web of Science ®Google Scholar
• Germeshausen M, Schulze H, Kratz C et al. An acquired G-CSF receptor mutation results in increased proliferation of CMML cells from a patient with severe congenital neutropenia. Leukemia19, 611–617 (2005).
   PubMedGoogle Scholar
• Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood109, 93–99 (2007).
   PubMed Web of Science ®Google Scholar
• Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer65, 2185–2195 (1990).
   PubMed Web of Science ®Google Scholar
• Ehlers S, Herbst C, Zimmerman M et al. Overexpression of the differentiation-defective G-CSF receptor isoform IV is associated with a high incidence of relapse in childhood acute myeloid leukemia treated with G-CSF. Presented at: 50th Annual Meeting of the American Society of Hematology, San Francisco, CA, USA, 6–9 December 2008.
   Google Scholar
• Bennett CL, Stinson TJ, Lane D, Amylon M, Land VJ, Laver JH. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med. Pediatr. Oncol.34, 92–96 (2000).
   PubMedGoogle Scholar
• Delorme J, Badin S, Le Corroller AG et al. Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol.25, 441–447 (2003).
   PubMedGoogle Scholar
• Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II–IV breast cancer. Oncol. Rep.10, 715–724 (2003).
   PubMed Web of Science ®Google Scholar
• Papaldo P, Lopez M, Marolla P et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J. Clin. Oncol.23, 6908–6918 (2005).
   PubMed Web of Science ®Google Scholar
• Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J. Pediatr. Hematol. Oncol.27, 449–451 (2005).
   PubMed Web of Science ®Google Scholar
• te Poele EM, Kamps WA, Tamminga RY, Leeuw JA, Postma A, de Bont ES. Pegfilgrastim in pediatric cancer patients. J. Pediatr. Hematol. Oncol.27, 627–629 (2005).
   PubMed Web of Science ®Google Scholar
• Andre N, Kababri ME, Bertrand P et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs18, 277–281 (2007).
   PubMed Web of Science ®Google Scholar